Elanco Animal Health Incorporated (ELAN) financial statements and ratios from SEC XBRL: revenue $5.2B (TTM), net margin -4.9%, revenue growth 6.2% YoY, P/E 89.4. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $4.71B |
| Revenue (TTM) | $5.2B |
| Net Margin | -4.9% |
| Operating Margin (TTM) | -2.7% |
| Net Debt / EBITDA | 5.6 |
| Revenue Growth (YoY) | 6.2% |
| EPS Growth (YoY) | -169.1% |
| FCF Growth (YoY) | -27.9% |
| P/E Ratio | 89.4 |
| EV / EBITDA | 26.1 |
| Price / Book | 1.82 |
| Price / Sales | 2.28 |
| FCF Yield | 3.1% |
| Altman Z-Score | 1.29 (distress) |
| Piotroski F-Score | 5/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ELAN overview · ELAN earnings · ELAN KPIs · ELAN documents · ELAN ownership · ELAN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.